Targeted Panel Assays:
Plasma-Safe-SeqS (PSS) Technology
Reliable detection of clinically relevant mutations in HPV-negative HNSCC
Ultra-sensitive detection of the most common Acute Myeloid Leukemia (AML) biomarkers with maximum efficiency.
Reliable detection of AML-MRD relevant and promising mutations. AML-MRD-SEQ detects 68 mutations across 20 genes, including established AML markers, such as IDH1, IDH2, and NPM1, and it demonstrates a significant potential for use as an investigational tool for other markers with prognostic values that are not yet well established.
Detection of mutations in the five most relevant targets for cancers (e.g., colorectal, pancreatic, gallbladder, ovarian, and lung) impacted by the RAS-RAF and PI3K signaling pathways.
BC-SEQ detects mutations in established and emerging predictive markers, resistance mutations, and frequently occurring genetic alterations in breast cancer.
|Plasma-Safe-SeqS panel||Clinically relevant gene regions||Intended uses|
|RAS-RAF-SEQ RAS-RAF Pathway||BRAF, KRAS, NRAS, AKT1, PIK3CA|
|HPV-SEQ & HPV Pathway||HPV 16, HPV 18|
|BC-SEQ & Breast Cancer||AKT1, ERBB2, ESR1, KRAS, PIK3CA, TP53|
|AML-MRD-SEQ & AML MRD||FLT3, IDH1, IDH2, NPM1, BCOR, BRAF, CEBPA, GATA2, JAK2, KIT, KRAS, NRAS, PRPF8, PTPN11, SETBP1, SF3B1, SRSF2, TP53, U2AF1, ZRSR2|
|HNSCC-SEQ & H&N HPV(-) cancers||CDKN2A, EGFR, ERBB2, FGFR3, HRAS, KRAS, NOTCH1, PIK3CA, PTEN, TP53|
Plasma-Safe-SeqS technology platform general test specifications
|Cell-free DNA analysis for solid tumors||Hematological malignancies|
|7 – 10 Business days|
Plasma-Safe-SeqS can detect between 5-7 mutant molecules (95% CI) irrespective of the amount of wildtype DNA present and/or the panel configuration. For 33 ng DNA input, this corresponds to 0.05-0.07% mutant allele frequency (MAF).